In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1331-1334

  Miyashita, Naoyuki ^a,b   Niki, Yoshihito ^a   Kishimoto, Toshio ^a   Nakajima, Masamitsu ^a   Matsushima, Toshiharu ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MINOCYCLINE; SPARFLOXACIN; TOSUFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL RATE; UNITED STATES;

EID: 0030995061     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1331     Document Type: Article

References (22)

1. Block, S., J. Hedrick, M. R. Hammerschlag, G. H. Cassell, and J. C. Craft. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. 14:471-477.
2. Emre, U., P. M. Roblin, M. Gelling, W. Dumornay, M. Rao, M. R. Hammerschlag, and J. Schachter. 1994. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch. Pediatr. Adolesc. Med. 148:727-732.
3. Grayston, J. T., L. A. Campbell, C.-C. Kuo, C. H. Mordhorst, P. Saikku, D. H. Thom, and S.-P. Wang. 1990. A new respiratory tract pathogen: Chlamydia pneumonia? strain TWAR. J. Infect. Dis. 161:618-625.
4. Grayston, J. T., C.-C. Kuo, S.-P. Wang, and J. Altman. 1986. A new Chlamydia psittaci strain. TWAR, isolation in acute respiratory tract infections. N. Engl. J. Med. 315:161-168.
5. Grayston, J. T., S.-P. Wang, C.-C. Kuo, and L. A. Campbell. 1989. Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases. Eur. J. Clin. Microbiol. Infect. Dis. 8:191-202.
6. Hammerschlag, M. R., C. L. Hyman, and P. M. Roblin. 1992. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:682-683.
7. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
8. Hammerschlag, M. R., P. M. Roblin, and G. H. Cassel. 1994. Microbiologic efficacy of azithromycin for the treatment of community-acquired lower respiratory tract infection due to Chlamydia pneumoniae, abstr. 283. In Program and abstracts of the 2nd International Conference on Macrolides, Azalides, and Streptogramins.
9. Hosaka, M., S. Kinoshita, A. Toyama, M. Otsuki, and T. Nishino. 1995. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J. Antimicrob. Chemother. 36:293-301.
10. Hosaka, M., T. Yasue, H. Fukuda, H. Tomizawa, H. Aoyama, and K. Hirai. 1992. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36:2108-2117.
11. Ishida, K., M. Kaku, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, H. Tanaka, T. Usui, K. Tomono, N. Suyama, H. Koga, S. Kohno, and K. Hara. 1994. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae. J. Antimicrob. Chcmother. 34:875-883.
12. Kishimoto, T., and R. Soejima. 1993. Current topics of chlamydial respiratory tract infections - special reference to the epidemiology and clinical findings of Chlamydia pneumoniae infections in Japan. Intern. Med. 32:934-937.
13. Kumamoto, Y., A. Matsumoto, A. Nagayama, R. Soejima, K. Hirai, S. Hashizume, and T. Hagiwara. 1992. Method for in vitra determination of chlamydial susceptibility (minimum inhibitory concentration; MIC) to antimicrobial agents. - Standard method of Japan Society of Chemotherapy (revision in 1991) -. Chemotherapy (Tokyo) 40:308-314.
14. Kumamoto, Y., A. Matsumoto, A. Nagayama, R. Soejima, K. Hirai, S. Hashizume, and T. Hagiwara. 1992. Method for in vitro determination of chlamydial susceptibility (minimal lethal concentration: MLC) to antimicrobial agents. - Standard method of the Japan Society of Chemotherapy (revision in 1991) -. Chemotherapy (Tokyo) 40:318-321.
15. Kuo, C.-C., and J. T. Grayston. 1988. In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob. Agents Chemother. 32:257-258.
16. Miyashita, N., and A. Matsumoto. 1994. Microbiology of chlamydiae - with emphasis on physicochemistry, antigenicity and drug susceptibility of Chlamydia pneumoniae -. Kawasaki Med. J. 20:1-17.
17. Miyashita, N., A. Matsumoto, Y. Kubota, M. Nakajima, Y. Niki, and T. Matsushima. 1996. Continuous isolation and characterization of Chlamydia pneumonia? from a patient with diffuse panbronchiolitis. Microbiol. Immunol. 40:547-552.
18. Miyashita, N., Y. Kanamoto, and A. Matsumoto. 1993. The morphology of Chlamydia pneumoniae. J. Med. Microbiol. 38:418-425.
19. Miyashita, N., Y. Kubota, M. Kimura, M. Nakajima, Y. Niki, R. Soejima, and A. Matsumoto. 1994. Characterization of a Chlamydia pneumoniae strain isolated from a 57-year-old man. Microbiol. Immunol. 38:857-864.
20. Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640.
21. Tomioka, H., H. Saito, and K. Sato. 1993. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob. Agents Chemother. 37:1259-1263.
22. Wakabayasi, E., and S. Mitsubashi. 1994. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 38:594-601.